Bispecific monoclonal antibody

Global Dog Vaccines Market Size/Share Envisaged to Reach USD 2,708.28 Million By 2032, at 5.7% CAGR: Research by Polaris Market Research

Retrieved on: 
Thursday, January 18, 2024

The escalating current of pet possession and the growing circumstance of pet humanization are causing the market to grow.

Key Points: 
  • The escalating current of pet possession and the growing circumstance of pet humanization are causing the market to grow.
  • The dog vaccine market segmentation is primarily based on vaccine type, disease type, duration of immunity, route of administration, and region.
  • The dog vaccine market size is expanding as more people acquire dogs, and there is a correlating escalation in demand for precautionary healthcare estimates involving vaccinations.
  • The dog vaccine market trends include the existence of several productive proxies for the CIRDC, encouraging the continual advancement of contemporary vaccines.

Medicenna Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Operational Highlights

Retrieved on: 
Tuesday, November 14, 2023

TORONTO and HOUSTON, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA; OTC: MDNAF), a clinical-stage company focused on the design and development of novel evolutionary superkines to create revolutionary immunotherapies, today announced financial results and corporate highlights for the second quarter of fiscal 2024, ended September 30, 2023.

Key Points: 
  • We look forward to reporting initial Phase 2 dose expansion data from both the monotherapy and combination arms during the first half of 2024,” concluded Dr.
  • Clinical update from the ABILITY study’s MDNA11 plus pembrolizumab Phase 2 combination arm expected in the first half of 2024.
  • Research and development expenses of $3.1 million were incurred during the quarter ended September 30, 2023, compared with $2.4 million incurred in the quarter ended September 30, 2022.
  • General and administrative expenses of $2.3 million were incurred during the quarter ended September 30, 2023, compared with $2.4 million during the quarter ended September 30, 2022.

IGM Biosciences Announces Third Quarter 2023 Financial Results

Retrieved on: 
Monday, November 13, 2023

MOUNTAIN VIEW, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the quarter ended September 30, 2023.

Key Points: 
  • MOUNTAIN VIEW, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the quarter ended September 30, 2023.
  • “During the third quarter, we continued to execute across our clinical development pipeline,” said Fred Schwarzer, Chief Executive Officer of IGM Biosciences.
  • Collaboration Revenue: For the third quarter of 2023, collaboration revenues were $0.5 million, compared to $0.3 million for the same period in 2022.
  • Research and Development (R&D) Expenses: For the third quarter of 2023, R&D expenses were $54.8 million, compared to $48.2 million for the same period in 2022.

New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)

Retrieved on: 
Saturday, December 9, 2023

An estimated 85 percent and 74 percent of patients who experienced a CR remained in response at 12 and 18 months, respectively.

Key Points: 
  • An estimated 85 percent and 74 percent of patients who experienced a CR remained in response at 12 and 18 months, respectively.
  • Safety findings were consistent with previous epcoritamab trials, and epcoritamab was generally well tolerated.
  • TEAEs leading to treatment discontinuation occurred in 19 percent of patients, and Grade 5 TEAEs occurred in 13 patients (10 percent).
  • “The data presented at ASH reinforce what we have seen from our epcoritamab research and believe that this investigational bispecific antibody could potentially represent an important treatment option for patients living with relapsed or refractory follicular lymphoma.

European Commission Approves Pfizer’s ELREXFIO® for Relapsed and Refractory Multiple Myeloma

Retrieved on: 
Friday, December 8, 2023

Pfizer Inc. (NYSE:PFE) today announced the European Commission (EC) has granted conditional marketing authorization for ELREXFIO® (elranatamab).

Key Points: 
  • Pfizer Inc. (NYSE:PFE) today announced the European Commission (EC) has granted conditional marketing authorization for ELREXFIO® (elranatamab).
  • "More than 50,000 Europeans are diagnosed with multiple myeloma each year, and too often, they face relapse and treatment resistance,” said Chris Boshoff, Chief Oncology Research and Development Officer and Executive Vice President, Pfizer.
  • The conditional marketing authorization for ELREXFIO is valid in all 27 EU member states as well as Iceland, Liechtenstein, and Norway.
  • This authorization follows the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) recommendation for a conditional marketing authorization on October 12, 2023.

Bispecific Antibodies: Structural Design, Production and Purification Strategies, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, November 22, 2023

TORONTO, Nov. 22, 2023 /PRNewswire-PRWeb/ -- Discover this groundbreaking webinar delving into the strategic approaches of bispecific antibody (BsAb) design, production and purification. BsAbs have become increasingly of interest by enabling new therapeutic applications for a variety of indications, including cancer, chronic inflammatory diseases, autoimmunity, neurodegeneration, bleeding disorders and infections. Currently, there are 12 bispecific antibodies approved worldwide.

Key Points: 
  • Attendees will learn the key considerations of bispecific antibody structural design and analysis of general design strategies.
  • The featured speaker will discuss production strategies and by-product purification plans for bispecific antibodies with different structures.
  • TORONTO, Nov. 22, 2023 /PRNewswire-PRWeb/ -- Discover this groundbreaking webinar delving into the strategic approaches of bispecific antibody (BsAb) design, production and purification.
  • Join this webinar to gain insights into the diverse applications, design considerations and production strategies of bispecific antibodies.

Compass Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 9, 2023

Transition to take place on January 9th 2024

Key Points: 
  • Transition to take place on January 9th 2024
    Ended the third quarter with $164 million in cash and marketable securities, providing cash runway for the company into 2026
    BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported third quarter and year-to-date, 2023 financial results.
  • During the first nine months of 2023, the Company used $28 million of cash to fund operations.
  • R&D expenses were $8.8 million for the quarter ended September 30, 2023, as compared to $9.8 million for the same period in 2022, a decrease of approximately $1.0 million or 10%.
  • G&A expenses were $3.1 million for the quarter ended September 30, 2023, as compared to $2.8 million for the same period in 2022, an increase of $0.3 million or 10%.

Jazz Pharmaceuticals and MD Anderson Announce Five-Year Collaboration to Evaluate Zanidatamab in HER2-Expressing Cancers

Retrieved on: 
Tuesday, November 7, 2023

DUBLIN and HOUSTON, Nov. 7, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and The University of Texas MD Anderson Cancer Center today announced a five-year strategic research collaboration agreement to evaluate zanidatamab, Jazz's investigational HER2-targeted bispecific antibody, in multiple HER2-expressing cancers.

Key Points: 
  • DUBLIN and HOUSTON, Nov. 7, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and The University of Texas MD Anderson Cancer Center today announced a five-year strategic research collaboration agreement to evaluate zanidatamab, Jazz's investigational HER2-targeted bispecific antibody, in multiple HER2-expressing cancers.
  • Jazz and MD Anderson will establish a joint steering committee to oversee the collaboration, which will fund multiple studies over its five-year term.
  • This effort builds upon a previous strategic collaboration between Jazz and MD Anderson focused on hematologic malignancies.
  • Zanidatamab has compelling anti-tumor activity across a broad range of HER2-positive cancers," said Rob Iannone, M.D., M.S.C.E., executive vice president, global head of research and development of Jazz Pharmaceuticals.

MacroGenics Provides Update on Corporate Progress and Third Quarter 2023 Financial Results

Retrieved on: 
Monday, November 6, 2023

ET

Key Points: 
  • ET
    ROCKVILLE, Md., Nov. 06, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended September 30, 2023.
  • Revenue: Total revenue was $10.4 million for the quarter ended September 30, 2023, compared to total revenue of $41.7 million for the quarter ended September 30, 2022.
  • R&D Expenses: Research and development expenses were $30.1 million for the quarter ended September 30, 2023, compared to $48.2 million for the quarter ended September 30, 2022.
  • SG&A Expenses: Selling, general and administrative expenses were $12.4 million for the quarter ended September 30, 2023, compared to $15.4 million for the quarter ended September 30, 2022.

Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Retrieved on: 
Friday, November 3, 2023

TORONTO and HOUSTON, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA), a clinical-stage immunotherapy company focused on the development of Superkines, today announced new preclinical data demonstrating proof of concept for the Company’s novel T-MASK (Targeted Metallo/protease Activated SuperKine) platform technology with the Company’s development candidate, MDNA113, at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (“SITC”) held in San Diego, CA, from November 1-5, 2023.

Key Points: 
  • “The results presented today demonstrates proof of concept with MDNA113, our first T-MASK candidate specifically designed to deliver bispecific IL-2-antiPD1 Superkine to cancers that express the tumor associate antigen, IL-13R⍺2.
  • MDNA113 has high selectivity and affinity for the IL-13 decoy receptor IL-13Rα2, a tumor associated antigen expressed by many aggressive solid tumors.
  • MDNA113 is fused via a protease sensitive linker (“PSL”) to MDNA223, containing a not-alpha, beta-enhanced IL-2 Superkine fused to anti-PD1 antibody.
  • A copy of the poster will be posted to the “ Events and Presentations ” page of Medicenna’s website following the conclusion of the meeting.